MISTER: Steam Therapy for BPH in real-world practice
Official title: MISTER Study: Minimally Invasive Steam Therapy - Russian Effectiveness Registry
Run by Sechenov University · NCT07723378 · Data updated 2026-11-12
This study tests Rezūm steam therapy for men with moderate-to-severe BPH and LUTS to see how well it works in real-world clinics.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | Men only |
| Enrollment | 1400 (estimated) |
| Sponsor | Sechenov University Academic / other |
| Locations | 1 site (Moscow) |
| Status | Recruiting |
| Started | August 1, 2026 |
| Main results expected | August 2027 |
| Study ends | September 2027 |
| Registry record updated | July 23, 2026 |
| Trial ID | NCT07723378 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Men with BPH experiencing moderate-to-severe LUTS (IPSS ≥8, QoL ≥3), prostate volume 30–150 cm³, Qmax ≤15 mL/s, and post-void residuals <300 mL who are considering Rezūm treatment.
✕Probably not a fit
Patients with active prostate cancer, acute urinary tract or prostate infections, neurogenic bladder, bladder stones, urethral strictures, prior prostate surgery, or those who do not consent to use of data may not benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The MISTER study is a multicenter registry that collects real-world outcomes of Rezūm minimally invasive water vapor therapy for benign prostatic hyperplasia. It aims to describe symptom changes, urinary flow, and safety after treatment in typical clinical settings. Eligible participants have BPH-related LUTS with specific prostate size and urinary flow criteria, and data are gathered from routine care rather than a controlled experimental environment. The registry seeks to identify factors linked to temporary urinary retention, need for repeat treatment, and ejaculatory changes, and to help standardize success criteria. Results will reflect everyday practice across several Russian medical centers.
Why it matters
Potential benefit: If successful, patients may experience sustained improvement in urinary symptoms and quality of life with a minimally invasive option that preserves ejaculation for many men.
How similar studies have gone: Prior clinical experiences with Rezūm show symptom relief and preserved ejaculation; this registry builds real-world evidence rather than a randomized trial, so findings may be complementary to controlled studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria * Lower urinary tract symptoms (IPSS ≥8 points; QoL ≥3 points) due to BPH * Prostate volume of 30-150 cm³ * Qmax ≤15 mL/s; post-void residual urine volume \<300 mL Non-Inclusion Criteria * Prostate cancer * Acute infections of the urinary tract, prostate, or scrotal organs * Neurogenic lower urinary tract dysfunction * Bladder stone(s) * Urethral stricture * Prior prostate surgery Exclusion Criteria * Patient refusal to allow use of medical data for scientific analysis * Missing or lost data required for analysis
Where it's running
-
Institute for Urology and Reproductive Health, Sechenov University
Moscow, Russia Recruiting
Study contacts
- Study coordinator: Vladislav Petov
- Email: pettow@mail.ru
- Phone: +7 925 351 75 49
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing MiLEP and standard EEP for treating prostate enlargement
This study is testing a new method called MiLEP against the standard treatment for prostate enlargement to see which one works better for men with urinary problems.
-
Transurethral Thermodilatation vs Prostatic Urethral Lift for BPH in men 50–80
This study tests whether Prolieve can match UroLift in relieving BPH symptoms in men 50–80 who haven’t had enough relief from medicines.
-
Oxiblume:CoQ10 (Ralivia) Therapy for Benign Prostatic Hyperplasia: a comparison to placebo
This study tests whether Oxiblume:CoQ10 (Ralivia) can improve symptoms for men with BPH compared to a placebo.
-
Early versus delayed catheter removal in men with sudden urinary retention
This trial will test whether removing the catheter after 3 days or after 14 days helps men with sudden urinary retention (usually from an enlarged prostate) urinate without the catheter.
-
Evaluating Tryptophan for Treating BPH Symptoms
This study is testing whether Tryptophan can help men with BPH symptoms feel better without the sexual side effects that come with usual treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.